Nuvectis Pharma AI Stock Analysis
Want to see NVCT full AI Analyst Report?
Nuvectis Pharma (NVCT) AI Stock Analysis
Nuvectis Pharma
(NASDAQ:NVCT)
NVCT’s score is primarily held back by weak financial performance (pre-revenue, widening losses, and ongoing cash burn), despite a solid debt-free balance sheet. The latest earnings call was a meaningful positive with a long stated cash runway and multiple near-term clinical/regulatory catalysts, but technicals remain neutral-to-soft and valuation metrics are limited by negative earnings and no indicated dividend.
Nuvectis Pharma (NVCT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $688.14M
- Dividend Yield
- ―
- Average Volume (3M)
- 203.98K
- Price to Earnings (P/E)
- -11.1
- Beta (1Y)
- 0.46
- Revenue Growth
- ―
- EPS Growth
- -41.15%
- Country
- US
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Nuvectis Pharma Business Overview & Revenue Model
Company Description
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engine...
Nuvectis Pharma Earnings Call Summary
The call was strongly positive, driven by the transformation into a late-stage development company, the China approval of NXP-100, encouraging NXP-100 and NXP-200 clinical data, substantial financing, and a cash runway into the second half of 2029. The primary challenges were the reported quarterly net loss, the unresolved FDA requirements for U.S. PNH development, and the need for additional NXP-200 solid tumor data, but these issues were outweighed by the number and significance of the stated achievements and upcoming catalysts.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects approximately $140 million in cash to fund operations into the second half of 2029 and beyond multiple value inflection points; it expects an update on the FDA interaction for NXP-100 by year end, approval in China for previously treated PNH patients in the first quarter of 27, an IND for another indication outside of PNH later this year, clinical trials in additional indications in the first half of 27, a US IND for NXP-200 by the end of the year and a US phase 1 b in early 27, additional NXP-200 phase 1b data in early 27, and NXP-900 clinical updates in the first half of 27; for NXP-100, the company’s goal is to file at least 1 IND by the end of the year and be in a position to start clinical trials as soon as possible in 2027, while NXP-200 may have as many as 15 to 17 patients in the BRAF relapse subset, with a 20 percent or 25 percent response rate considered success.
Nuvectis Pharma Financial Statement Overview
Summary
Overall fundamentals are mixed for an early-stage biotech: the balance sheet is a strength with $0 debt and materially improved equity/assets, but the company remains pre-revenue with widening losses and sustained negative operating/free cash flow, including an elevated TTM cash burn.
Income Statement
12Very NegativeBalance Sheet
66PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -52.51M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
| Net Income | -50.45M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
Balance Sheet | ||||||
| Total Assets | 140.84M | 31.71M | 18.61M | 19.18M | 20.41M | 6.66M |
| Cash, Cash Equivalents and Short-Term Investments | 140.71M | 31.63M | 18.53M | 19.13M | 19.99M | 5.74M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.19M | 13.30M | 8.89M | 6.98M | 6.19M | 17.66M |
| Stockholders Equity | 126.65M | 18.41M | 9.71M | 12.20M | 14.22M | -11.01M |
Cash Flow | ||||||
| Free Cash Flow | -40.29M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Operating Cash Flow | -40.29M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 145.56M | 29.11M | 11.65M | 15.09M | 27.81M | 15.25M |
Nuvectis Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Positive. The current price of 21.00 is above the 20-day moving average (MA) of 19.34, above the 50-day MA of 20.80, and above the 200-day MA of 15.00, indicating a bullish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 56.92 is Neutral, neither overbought nor oversold. The STOCH value of 84.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCT.
Nuvectis Pharma Risk Analysis
Nuvectis Pharma disclosed 52 risk factors in its most recent earnings report. Nuvectis Pharma reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksNuvectis Pharma Peers Comparison
Overall Rating
- NVCT57Neutral
OBIO50Neutral
NKTX45Neutral
PYXS41Neutral
MOLN39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NVCT | 57Neutral | $724.92M | -11.11 | -119.87% | ― | ― | -41.15% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| OBIO | 50Neutral | $344.40M | -6.75 | -125.93% | ― | 1007.38% | 50.23% |
| NKTX | 45Neutral | $96.80M | -0.85 | -48.58% | ― | ― | -24.79% |
| PYXS | 41Neutral | $194.96M | -1.26 | -252.36% | ― | 291.42% | 18.90% |
| MOLN | 39Underperform | $125.16M | -1.86 | -79.25% | ― | ― | 11.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | 21.00 | 15.08 | 254.73% | |
| NKTX | Nkarta, Inc. | 1.48 | -0.40 | -21.28% | |
| OBIO | Orchestra Biomed Holdings, Inc. | 6.01 | 1.83 | 43.78% | |
| GLSI | Greenwich Lifesciences, Inc. | 16.09 | 7.89 | 96.22% | |
| MOLN | Molecular Partners Ag | 3.09 | -1.19 | -27.80% | |
| PYXS | Pyxis Oncology, Inc. | 1.64 | -2.84 | -63.39% |
Nuvectis Pharma Corporate Events
Nuvectis Pharma Launches New $200 Million ATM Program
PositiveOn August 21, 2026, Nuvectis Pharma, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market equity offering program for its common stock under a fresh $200 million shelf registration on Form S-3. Under the...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026